Evidence map›Paper›PMID 28706748›Full record

ReviewParkinson's disease2017

Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease: An Institutional Experience and Review.

Shazia Mirza, Umar Yazdani, Richard Dewey Iii, Neepa Patel, Richard B Dewey, Svjetlana Miocinovic, Shilpa Chitnis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Parkinson's disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Neuromodulation for substance addiction in human subjects: A review.Neuroscience and biobehavioral reviews · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shazia MirzaDepartment of Neurology and Neurotherapeutics, UT Southwestern, Dallas, TX, USA.ORCID 0000-0002-8497-4333
Umar YazdaniDepartment of Neurology and Neurotherapeutics, Section of Movement Disorders, UT Southwestern, Dallas, TX, USA.
Richard Dewey IiiUT Southwestern Medical School, Dallas, TX, USA.
Neepa PatelHenry Ford Hospital, Detroit, MI, USA.ORCID 0000-0002-0073-9783
Richard B DeweyDepartment of Neurology and Neurotherapeutics, Section of Movement Disorders, UT Southwestern, Dallas, TX, USA.
Svjetlana MiocinovicEmory University, Atlanta, GA, USA.
Shilpa ChitnisDepartment of Neurology and Neurotherapeutics, Section of Movement Disorders, UT Southwestern, Dallas, TX, USA.ORCID 0000-0002-0545-5456

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep Brain Stimulation (DBS) has revolutionized the lives of patients of Parkinson disease, offering therapeutic options to those not benefiting entirely from medications alone. With its proven track record of outperforming the best medical management, the goal is to unlock the full potential of this therapy. Currently, the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN) are both viable targets for DBS, and the choice of site should focus on the constellation of symptoms, both motor and nonmotor, which are key determinants to quality of life. Our article sheds light on the specific advantages and drawbacks of the two sites, highlighting the need for matching the inherent properties of a target with specific desired effects in patients. UT Southwestern Medical Center has a robust and constantly evolving DBS program and the narrative from our center provides invaluable insight into the practical realities of DBS. The ultimate decision in selecting a DBS target is complex, ideally made by a multidisciplinary team, tailored towards each patient's profile and their expectations, by drawing upon scientific evidence coupled with experience. Ongoing research is expanding our knowledge base, which should be dynamically incorporated into an institute's DBS paradigm to ensure that patients receive the optimal therapy.

Identifiers

PMID28706748
PMCPMC5494569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.